ACTG Unveils IPACE-HIV Study: A Groundbreaking Approach to Frailty Intervention
Chapel Hill, N.C., January 9, 2026
ACTG, a renowned global clinical trials network specializing in HIV and infectious diseases, has embarked on a groundbreaking initiative with the launch of the IPACE-HIV study. This study, known as A5426, marks a significant advancement in the field of HIV research, focusing on a novel approach to combat frailty in individuals living with HIV.
Unraveling the Frailty Mystery
People living with HIV often encounter accelerated aging, experiencing diseases and conditions like frailty at younger ages compared to the general population. Even those with well-managed HIV on antiretroviral treatment are not immune to this phenomenon. Current interventions primarily rely on non-pharmacological methods, such as exercise, nutritional support, and managing comorbidities, which can be challenging and may not always provide optimal results.
A Revolutionary Senolytic Approach
IPACE-HIV introduces a revolutionary strategy by utilizing dasatinib and quercetin, a pair of senolytics. These drugs target cellular senescence, the cells responsible for biologic aging. Previous clinical trials have demonstrated the potential of this regimen in reversing frailty symptoms, but the IPACE-HIV study is the first to specifically include individuals living with HIV.
Study Details
The phase 2, double-blind, randomized IPACE-HIV study aims to assess the safety, tolerability, and effectiveness of dasatinib and quercetin in enhancing physical function in HIV-positive individuals who are frail or at risk of becoming frail. This comprehensive approach holds the promise of improving the quality of life for those living with HIV, offering a glimmer of hope in the ongoing battle against HIV-related frailty.
For more information and to stay updated on the study's progress, visit https://www.globenewswire.com/news-release/2026/01/09/3216126/0/en/ACTG-Launches-IPACE-HIV-to-Study-Frailty-Intervention.html.
This study represents a significant step forward in HIV research, offering a glimmer of hope for a healthier future for individuals living with HIV. Stay tuned for further updates as ACTG continues to innovate and drive progress in the fight against HIV-related frailty.
